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Abstract
Cyclooxygenase (COX), also known as prostaglandin H synthase, catalyses the
formation of prostaglandins from arachidonic acid. It can be expressed in
response to various stimuli, such as hormones, mitogens, cytokines, other
inflammatory mediators and growth factors. The product of COX-2 activity has
been implicated in carcinogenesis by promoting angiogenesis, inhibiting
apoptosis, increasing cell invasion and stimulating cell proliferation. It has also
been proved that the regular intake of non-steroidal anti-inflammatory drugs
(NSAIDs) decreases the risk of developing colon and breast cancers. Thus, it
speaks for an important role of COX-2 in growth processes of various types of
neoplasms. The connection between COX-2 activity and carcinogenesis has also
been examined in human thyroid neoplasms. COX-2 overexpression has been
reported in thyroid cancers and also in inflammatory conditions. In consequence
there is significant interest whether COX-2 could be of importance as a molecular
marker of malignancy in the case of thyroid carcinoma. 
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the enzyme
cyclooxygenase (COX), which is the key enzyme in biosynthesis of
proinflammatory prostaglandins from arachidonic acid [1]. This notion has
been supported by suppression of inflammatory responses in a number
of clinical courses with experimental animals, followed by analysis of
human cell cultures. It has been proved that regular intake of NSAIDs
decreases the risk of developing colon cancer [2, 3]. Non-steroidal anti-
inflammatory drugs have also been of interest for researchers, as to
whether their regular intake could possibly decrease the risk of developing
other types of cancer. 
Cyclooxygenase enzymes
The cyclooxygenases are a group of enzymes that catalyse the formation
of prostaglandins from arachidonic acid. The COX-1 gene is located on
chromosome 9q and encodes a 66-kDa protein, whereas the COX-2 gene
is found on chromosome 1 and encodes a 70-kDa protein, which has 61%
homology with the product of COX-1 [4].
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Cyclooxygenase-1 is a constitutive form, thought
to be a housekeeping gene, with constant levels of
expression in most tissues. It is indispensable in
order to maintain physiological functions, such as
gastric cytoprotection, vascular homeostasis and
kidney function (mediated by prostaglandins); also
it regulates normal platelet function, which is
mediated by thromboxane [5]. As regards the
thyroid gland, COX-1 has not been a subject of
excessive interest, perhaps except for medullary
thyroid carcinoma [6, 7]. On the other hand, COX-2
is expressed at baseline levels and is frequently
undetectable in normal tissues. The relation of COX-2
to pathological phenomena in the thyroid gland
seems to be much closer and is a subject of
intensive research. Additionally, it should be
mentioned that lipoxygenase (LOX), like COX-1, has
not aroused more interest as regards the thyroid.
Besides NSAIDs, also corticosteroids decrease
COX-2 expression or downregulate transcript
isoforms of COX-2 [8, 9]. It has recently been
reported that aurothiomalate inhibits COX-2
expression in chondrocytes and in human cartilage,
possibly through its effects on COX-2 mRNA stabi  -
lity [10]. Also, studies on certain plant extracts’
effect on COX-2 expression in cancer cells are being
conducted, but the subject requires further
elucidation [11].
Cyclooxygenase-2 and carcinogenesis
It can be expressed in response to various stimuli,
such as hormones, mitogens, cytokines, other
inflammatory mediators and growth factors via
protein kinase C and Ras-mediated signalling [12, 13].
The product of COX-2 activity has been implicated
in carcinogenesis by promoting angiogenesis,
inhibiting apoptosis, increasing cell invasion and sti  -
mu lating cell proliferation [14-17]. It also modulates
vascular endothelial growth factor (VEGF) synthesis;
this action promotes angiogenesis and decreases
immunity towards cancer cells [18, 19].
Recent studies have shown that up-regulation
of COX-2 is associated with numerous neoplasms,
including head and neck squamous cell, colorectal,
breast, lung, skin, stomach, liver, pancreas, bladder,
ovary and prostate cancers [20-35]. Epidemiological
data suggest that the regular use of NSAIDs can
significantly lower the risk of developing breast
cancer, by approximately 50%. A prospective study
of over 600,000 adults has indicated that aspirin
use decreases the risk of colon cancer by up to
50%. A prospective cohort of 49,700 male health
professionals has shown that a regular intake of
aspirin lowers the risk of metastatic and fatal colon
cancers, whereas “The Nurses’ Health Study” has
found a decreased risk of colorectal cancer among
women taking two or more aspirin tablets per
week, for 10 or more consecutive years [36, 37].
No epidemiological and/or randomized studies
have – so far – been performed in humans to
determine the protective properties of selective
COX-2 inhibitors, but experimental animal data are
fairly promising. COX-2 knockout mice develop
about 75% fewer chemically induced skin papilloma
[38]. In another study, null mutation for COX-2 in
Apc∆716 mice (a murine model of familial
adenomatosis) caused a marked reduction of
intestinal polyps and suppressed angiogenesis
because of lowered expression of VEGF.
Administration of COX-2 inhibitor caused further
polyp reduction in that case [39, 40].
Some of the published studies suggest an
important relationship between COX-2 activity and
the severity of illness, especially in carcinomas of
the gastrointestinal tract. It concerns mostly the
depth of invasion, the size of the tumour and the
amount of metastases into lymph nodes. In these
cases, the main source of increased COX-2 protein
product is not fibroblasts or proinflammatory cells
but tumour cells themselves [13].
Cyclooxygenase-2 and thyroid cancer
Thyroid cancer is the most common endocrine
malignancy and its most frequent types include
well-differentiated thyroid cancers – papillary (PTC)
and follicular (FTC) types, accounting for
approximately 95% of all thyroid cancers.
The connection between COX-2 activity and
carcinogenesis has also been examined in human
thyroid neoplasms. The involvement of the COX
pathway in the process of inflammation and in
cellular growth in the thyroid has been considered.
Interestingly, in the study of Larson et al. [41],
patients with Hashimoto thyroiditis were three
times more likely to have thyroid cancer, suggesting
a strong link between chronic inflammation and
cancer development.
There are also many well-known genetic
alterations associated with thyroid cancer that could
account for an increase in COX-2 expression. Ras
oncogene mutations have been found with high
frequency in benign and malignant thyroid tumours,
in all stages of human thyroid tumourigenesis 
[42, 43]. Fibroblasts, transformed with a mutant 
Ha-Ras oncogene respond with a rapid induction of
COX-2 [44]. Also, Ha-Ras expression in intestinal
epithelial cells leads to expression of COX-2 [45].
Another genetic factor is the RET  proto-
oncogene. It has previously been shown to activate
Ras, and thus it could indirectly lead to COX-2
activation. Whether RET could activate COX-2 in any
other way is a matter of further investigation [46].
All but one of the conducted studies demonstrate
overexpression of COX-2 in cases of PTC and FTC.
In the immunohistochemical study of Ito et al. [47],
there were 9 COX-2-negative cases out of 49 PTCArch Med Sci 5, October / 2010 655
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(18.4%). The authors also suggested a significant
reduction of COX-2 levels in elderly patients (above
54 years old), in patients with large tumours and
with advanced disease stages, as well as with the
presence of solid, scirrhous or trabecular growth
pattern. 
However, in the study of Kajita et al. [48] and
Garcia-Gonzales et al. [49] age was associated with
an increased incidence of PTC. The results of Kajita
et al. [48] did not show any significant differences
in COX-2 expression between normal thyroid tissue
and PTC, because of the observed variation in
mRNA levels. The authors also performed an in vitro
study with the TPC-1 thyroid carcinoma cell line and
NS-398, a COX-2 enzymatic activity specific
inhibitor, showing suppression of tumour cell
growth. They confirmed the role of COX-2 in the
growth of papillary thyroid cell lines [48]. 
Cornetta et al. [50] examined a variety of thyroid
tissue specimens. COX-2 staining was not observed
in specimens obtained from normal thyroid tissue,
multinodular goitre, or anaplastic carcinoma. An
analysis of Hashimoto’s thyroiditis revealed COX-2
expression in follicular epithelium and lymphocytic
infiltrates, as well as in cells of FTC and PTC [50].
The immunohistochemical study of Lee et al. [51]
showed prominent expression of COX-2 in
thyroiditis, and in benign and malignant thyroid
lesions, but not in normal thyroid tissue. Nor did
the authors observe any difference in the levels of
COX-2 expression between different tumour tissue
types. Because of the same intensity of COX-2
staining found in thyroiditis, and benign and
malignant thyroid lesions, the authors concluded
that COX-2 expression is unlikely to be related to
the progression of thyroid disease.
Specht et al. [52] reported overexpression of
COX-2 in 8 out of 10 cases of thyroid cancer, specific
for tumour cells but not for surrounding stroma.
They found that both COX-2 mRNA and protein
increase in malignant thyroid nodules, when
compared to benign nodules and adjacent normal
thyroid tissue. 
The results of experiments with Apc∆716
knockout mice suggest that the induction of 
COX-2 is a very early event in colon carcinogenesis.
That thesis has been supported by Garcia-Gonzales
et al. [49], who suggest that even though COX-2
plays an important role in the progression of all
thyroid cancers, in the case of PTC it seems to be
more important only in the early stages of the
cancer.
Rather limited data can be traced on the role of
COX-2 in follicular neoplasms, due to the small
number of patients enrolled into clinical studies.
FTC is believed to arise from pre-existing follicular
thyroid adenoma (FTA), indicating that FTA is
a prominent candidate for a precursor of FTC,
although this statement is still to be confirmed. In
the largest published series of cases evaluating
follicular neoplasms with COX-2, Nose et al. [53]
assessed immunoreactivity in 41 FTC and 23 FTA;
they observed strong COX-2 expression in all the
cases. In the earlier cited paper by Ito et al. [47], the
authors performed immunohistochemical staining
of COX-2 in 22 FTC and 15 FTA. Cyclooxygenase-2
overexpression was found in 40.9% of FTC and 20%
of FTA but without any statistical significance in
COX-2 expression between those two clinical
entities. Cyclooxygenase-2 overexpression was also
found in the study of Haynik et al. [54]; that study
included 34 patients with FTC and demonstrated
increased COX-2 expression in 26% of them. There
was no association between positive staining for
COX-2 and other prognostic indicators (vascular
invasion, capsular penetration, necrosis or Hürthle
cell lesion) but the authors found a higher
percentage of recurrences or metastases and of
tumours that caused death in cases with COX-2-
positive staining [54].
On the other hand, the experimental study by
Fuhrer et al. [55], using real time PCR, showed
similar COX-2 mRNA expression levels in benign
and malignant follicular neoplasms, normal thyroid
tissue and Graves’ disease samples. The authors
concluded that COX-2 usefulness as a molecular
marker for follicular thyroid neoplasia is markedly
limited.
Cyclooxygenase-2 and thyroiditis
Cyclooxygenase-2 overexpression has been
reported not only in thyroid cancers but also in
inflammatory conditions, such as thyroiditis. Chronic
inflammation, leading to neoplastic transformation
by promoting genomic instability, is a well
established clinical phenomenon. The relation of
thyroid neoplasm to Hashimoto disease has already
been reported in a very early paper [56]. 
An association between Hashimoto thyroiditis
and thyroid cancer remains controversial, with
various authors reporting different frequencies, e.g.,
as high as 43.8% [41] or 11-36% [57]. Another study
shows that transformed thyrocytes were able to
induce COX-2 expression in follicular cells and to
secrete IL-6 in response to IL-1β and TNF-α [58].
Therefore, COX-2 expression in Hashimoto’s
thyroiditis may predispose the thyroid follicular
epithelium to secrete proinflammatory cytokines,
such as IL-6, potentiating an inflammatory response
and the risk of developing thyroid carcinoma [50].
Enhanced expression of COX-2 in lymphocytic
thyroiditis (Hashimoto’s thyroiditis) suggests an
important role of this enzyme in the inflammatory
processes of the thyroid gland. There have 
been several studies supporting this thesis, based
on immunohistochemical analysis, showing656 Arch Med Sci 5, October / 2010
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overexpression of COX-2 in inflammatory thyroid
tissue [49-53]. However, in a recent study, Lo et al.
[59], using immunohistochemical evaluation of
examined specimens, did not detect COX-2
expression in lymphocytic thyroiditis.
In conclusions, the usefulness of COX-2 as
a marker of thyroid malignancy has been chal  -
lenged, but its potential role in carcinogenesis has
aroused significant interest. 
Fine needle aspiration biopsy has become
a critical component in the management of thyroid
nodules. It allows the number of cases requiring
surgical treatment to be decreased from 67% to
44%. Also the percentage of surgically treated
carcinomas in those nodules increased from 14%
up to 29% [60]. Preoperative discrimination of
thyroid malignancy, using not only cytopathology
but also a molecular marker, would enhance proper
diagnosis. 
The frequent negativity of COX-2 staining in
undifferentiated thyroid carcinomas and FTC
indicates that COX-2 is not always useful as
a marker of malignancy. When discussing this
matter, we should consider the important finding
that COX-2 expression was found to be significantly
higher in PTC. Therefore, its application in diag  -
nosing thyroid malignancy would be limited to PTC
cases. Accordingly, COX-2 expression has been
documented in a relatively large number of patients
with PTC. Therefore, it could be useful in patients
with diagnostic difficulties and suspicion of PTC.
Due to promising preclinical data, there are some
clinical studies assessing the efficacy of selective
COX-2 inhibitors in various malignancies, either
alone or in combination with other treatment
possibilities. Based on the above-mentioned studies,
it would be important to establish whether selective
COX-2 inhibitors could play some role in prevention
of thyroid malignancies.
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